GlaxoSmithKline (NYSE: GSK) reported Q1 EPS of $1.20, $0.18 better than the analyst estimate of $1.02. Revenue for the quarter came in at $10.06 billion versus the consensus estimate of $9.48 billion.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.